Iceland to Increase Access to New Drugs by Adjusting Pricing Policy

Iceland's healthcare system is taking a significant step forward in ensuring its citizens have access to the latest medical advancements. For too long, our nation has lagged behind its Nordic counterparts in adopting new and potentially life-saving drugs. This is not merely an inconvenience; it represents a tangible barrier to care for those who could benefit most.

The decision by the health authorities to shift from a lowest-price benchmark to a Nordic average for drug pricing is a crucial policy change. It acknowledges the reality that an overly aggressive low-price strategy can deter pharmaceutical companies from bringing their innovations to our shores. This new approach seeks a vital equilibrium: balancing the need for fiscal responsibility with the imperative of providing timely and effective treatments.

“

By looking at the Nordic average price, we are seeking to create a balance between cost and access, between responsibility and progress, and between being competitive as a market while at the same time being sensible in the allocation of funds. These are steps towards a more realistic and sustainable approach.

As highlighted by Frumtök, the association of innovative pharmaceutical manufacturers in Iceland, this move is a welcome development. Their data shows Iceland adopting a mere 34% of new drugs compared to Germany's 90% and Denmark's 60%. This stark contrast underscores the need for a more pragmatic and forward-thinking policy. The previous approach, implemented after the 2008 financial crisis, created a significant hurdle for new drug introductions.

This policy adjustment is not just about pharmaceuticals; it's about the well-being of the Icelandic people. Improved access to cutting-edge medicines can reduce the burden on our healthcare system and minimize illness-related absences from work and daily life. It signifies a commitment to progress and a recognition that staying competitive in healthcare requires adapting our strategies to global standards while remaining mindful of our unique position as a smaller market.

“

The decision by the government after the crash to always aim for the lowest price in the Nordic countries has been a real market barrier for new drugs, both because of the impact on pricing in other countries and because of other costs. Iceland is a small market that nevertheless adheres to the same demands as large countries. The minister's statement is therefore a very important change in direction that we welcome.